Scott Burrows Purchases Spyre Therapeutics Shares
CFO Scott Burrows acquired 15,000 shares of Spyre Therapeutics, Inc. on June 25, 2026.
Key Points
- Scott Burrows, CFO of Spyre Therapeutics, purchased 15,000 shares at $14.50 each on June 25, 2026, totaling $217,500.
- Spyre Therapeutics, Inc., a biotech firm, trades on NasdaqGS under SYRE, with a market cap of $7.7 billion and a 52-week high of $102.06.
- Analysts maintain a strong buy consensus for SYRE, with a mean price target of $100.47 among 15 analysts.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Scott Burrows, the Chief Financial Officer of Spyre Therapeutics, Inc. (NASDAQ: SYRE), purchased 15,000 shares of the company on June 25, 2026. The shares were bought at an average price of $14.50 each, amounting to a total transaction value of $217,500. This move was not part of a pre-arranged trading plan.
Insider Buying and Selling at Spyre Therapeutics, Inc.
On the same day, Scott Burrows sold 15,000 shares at an average price of $87.13 each. Additionally, Fairmount Funds Management LLC executed several transactions on June 23, involving both purchases and sales of Spyre Therapeutics shares.
Other Institutional Activity in Spyre Therapeutics
FMR LLC increased its holdings in Spyre Therapeutics by 142,205 shares, bringing its total to 11,781,024 shares valued at approximately $594.2 million. BlackRock, Inc. slightly trimmed its position by 880 shares, maintaining 5,521,221 shares worth about $278.5 million. Meanwhile, Perceptive Advisors LLC significantly boosted its stake by 714,000 shares, ending with 3,783,225 shares valued at roughly $190.8 million.
Spyre Therapeutics, Inc. Stock Down 2.7%
As of Saturday, shares of Spyre Therapeutics traded near $88.67. The company, with a market capitalization of approximately $7.7 billion, operates in the biotechnology sector. Despite not being profitable, Spyre has a forward P/E ratio of -28.34 and a high beta of 3.06, indicating volatility. The stock's 52-week range spans from $14.00 to $102.06, with a 50-day moving average of $75.57.
$SYRE stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On June 23, 2026, Deutsche Bank maintained its buy rating on Spyre Therapeutics, setting a price target of $135. BTIG also kept its buy rating with a $112 target on June 16. Overall, the consensus among 15 analysts is a strong buy, with an average target price of $100.47.
About Spyre Therapeutics
Spyre Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts. It focuses on developing treatments for inflammatory bowel disease and rheumatic diseases. Notable projects include SPY001, a monoclonal antibody for ulcerative colitis and Crohn's disease, and other clinical-stage programs targeting various immune system pathways. The company, led by CEO Dr. Cameron Turtle, was founded in 2013 and employs 112 people.
Bottom Line
Scott Burrows' purchase of Spyre Therapeutics shares highlights insider confidence in the company's prospects. Investors often watch insider transactions for potential insights into a company's future. While 13F filings and insider trades offer valuable information, they reflect past actions and may not indicate current holdings or future moves.
Get Spyre Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $SYRE, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.